Company: ARMP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077648
Chunk: 26

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 26
---
 provide that directors may be removed only for                                                                                      
 cause by the holders of not less than two-thirds of the shares entitled to elect the director or directors whose removal is sought; |

| · | require the vote of the holders of at least two-thirds                                                       
 of the issued and outstanding shares to amend or repeal certain provisions of our articles of incorporation; |

| · | require the vote of the holders of at least two-thirds                                                                      
 of the issued and outstanding shares to approve a “Business Combination” (as defined in our articles of incorporation) that 
 is not approved by the “Continuing Directors”;                                                                              |

| · | require the approval of a majority of the Continuing                                                                                     
 Directors to adopt, amend or repeal the bylaws that may be amended or repealed by the board of directors and require the approval of the 
 holders of not less than two-thirds of the outstanding shares to adopt, amend or repeal our bylaws; and                                  |

| · | does not provide for cumulative voting rights. |

NYSE American Listing

Our common stock is listed
on the NYSE American under the symbol “ARMP.”

Transfer Agent and Registrar

The transfer agent and registrar
for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar’s address is 150 Royall Street, Canton,
MA 02021.

<div align='center'>17

DESCRIPTION OF THE DEBT SECURITIES</div>

As of the date of this prospectus,
we have no debt securities issued and outstanding.

The following description,
together with the additional information we include in any applicable prospectus supplement, summarizes the material terms and provisions
of the debt securities that we may offer under this prospectus. While the terms we have summarized below will apply generally to any future
debt securities we may offer, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable
prospectus supplement. The terms of any debt securities we offer under a prospectus supplement may differ from the terms we describe below.

We will issue notes under
an indenture, which we will enter into with the trustee named in the indenture. Any indenture will be qualified under the Trust Indenture
Act of 1939. You should read the summary below, the applicable prospectus supplement and the provisions of the applicable indenture and
any related security documents, if any, in their entirety before investing in our debt securities.

We will describe in each prospectus
supplement the following terms relating to a